METTL4 and METTL5 as biomarkers for recurrence-free survival in hepatocellular carcinoma patients.

IF 3 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2025-02-01 Epub Date: 2024-12-20 DOI:10.1080/14796694.2024.2442296

Jialing Zhao, Ruiqi Sun, Liang Zhi, Danjing Guo, Sunbin Ling, Xiangnan Liang, Jianhui Li, Changku Jia

{"title":"METTL4 and METTL5 as biomarkers for recurrence-free survival in hepatocellular carcinoma patients.","authors":"Jialing Zhao, Ruiqi Sun, Liang Zhi, Danjing Guo, Sunbin Ling, Xiangnan Liang, Jianhui Li, Changku Jia","doi":"10.1080/14796694.2024.2442296","DOIUrl":null,"url":null,"abstract":"Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths, with high rates of postoperative recurrence. Identifying reliable biomarkers for predicting recurrence is critical for improving patient outcomes. This study investigates the predictive value of m6A methylation-related genes, METTL4 and METTL5, on HCC recurrence after surgery.Research design and methods: We analyzed METTL4 and METTL5 expression in HCC and adjacent non-cancerous tissues using the TCGA database and evaluated their levels in surgical samples from 67 hCC patients. A recurrence risk model was developed and validated in an external cohort of 65 patients.Results: METTL4 and METTL5 were significantly overexpressed in HCC tissues. High expression correlated with shorter recurrence-free survival (RFS). The model stratified patients into high, medium, and low-risk groups with 3-year RFS rates of 18.75%, 69.70%, and 93.75%, respectively.Conclusions: METTL4 and METTL5 expression levels are strong predictors of HCC recurrence. The risk model offers a novel approach for postoperative management of HCC.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"331-340"},"PeriodicalIF":3.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11792863/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2024.2442296","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/20 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths, with high rates of postoperative recurrence. Identifying reliable biomarkers for predicting recurrence is critical for improving patient outcomes. This study investigates the predictive value of m6A methylation-related genes, METTL4 and METTL5, on HCC recurrence after surgery.

Research design and methods: We analyzed METTL4 and METTL5 expression in HCC and adjacent non-cancerous tissues using the TCGA database and evaluated their levels in surgical samples from 67 hCC patients. A recurrence risk model was developed and validated in an external cohort of 65 patients.

Results: METTL4 and METTL5 were significantly overexpressed in HCC tissues. High expression correlated with shorter recurrence-free survival (RFS). The model stratified patients into high, medium, and low-risk groups with 3-year RFS rates of 18.75%, 69.70%, and 93.75%, respectively.

Conclusions: METTL4 and METTL5 expression levels are strong predictors of HCC recurrence. The risk model offers a novel approach for postoperative management of HCC.

查看原文本刊更多论文

METTL4和METTL5作为肝细胞癌患者无复发生存的生物标志物

背景：肝细胞癌（HCC）是癌症相关死亡的主要原因，术后复发率高。确定可靠的生物标志物来预测复发对于改善患者预后至关重要。本研究探讨m6A甲基化相关基因METTL4和METTL5对肝癌术后复发的预测价值。研究设计和方法：我们使用TCGA数据库分析了METTL4和METTL5在HCC和邻近非癌组织中的表达，并评估了67例HCC患者手术样本中METTL4和METTL5的表达水平。在65例患者的外部队列中建立并验证了复发风险模型。结果：METTL4和METTL5在HCC组织中显著过表达。高表达与较短的无复发生存期（RFS）相关。该模型将患者分为高、中、低危组，3年RFS分别为18.75%、69.70%和93.75%。结论：METTL4和METTL5表达水平是HCC复发的有力预测因子。该风险模型为肝癌术后治疗提供了一种新的方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.